Patents by Inventor Gregory Babcock

Gregory Babcock has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Nucleic acid molecules encoding antibodies to a proliferation-inducing ligand (APRIL)
    Patent number: 10981982
    Abstract: Antibody molecules that specifically bind to APRIL are disclosed. The antibody molecules can be used to treat, prevent, and/or diagnose disorders, such as IgA nephropathy.
    Type: Grant
    Filed: June 25, 2020
    Date of Patent: April 20, 2021
    Assignee: VISTERRA, INC.
    Inventors: James R. Myette, Zachary Holmes Shriver, Karthik Viswanathan, Andrew M. Wollacott, Hedy Adari-Hall, Boopathy Ramakrishnan, Gregory Babcock
  • Antibody molecules to a proliferation-inducing ligand (APRIL)
    Patent number: 10968270
    Abstract: Antibody molecules that specifically bind to APRIL are disclosed. The antibody molecules can be used to treat, prevent, and/or diagnose disorders, such as IgA nephropathy.
    Type: Grant
    Filed: June 25, 2020
    Date of Patent: April 6, 2021
    Assignee: VISTERRA, INC.
    Inventors: James R. Myette, Zachary Holmes Shriver, Karthik Viswanathan, Andrew M. Wollacott, Hedy Adari-Hall, Boopathy Ramakrishnan, Gregory Babcock
  • Method of using anti-APRIL (a proliferation-inducing ligand) antibodies to reduce IGA
    Patent number: 10954296
    Abstract: Antibody molecules that specifically bind to APRIL are disclosed. The antibody molecules can be used to treat, prevent, and/or diagnose disorders, such as IgA nephropathy.
    Type: Grant
    Filed: June 10, 2020
    Date of Patent: March 23, 2021
    Assignee: VISTERRA, INC.
    Inventors: James R. Myette, Zachary Holmes Shriver, Karthik Viswanathan, Andrew M. Wollacott, Hedy Adari-Hall, Boopathy Ramakrishnan, Gregory Babcock
  • Method of using anti-APRIL (a proliferation-inducing ligand) antibodies to reduce IGA
    Patent number: 10919960
    Abstract: Antibody molecules that specifically bind to APRIL are disclosed. The antibody molecules can be used to treat, prevent, and/or diagnose disorders, such as IgA nephropathy.
    Type: Grant
    Filed: June 10, 2020
    Date of Patent: February 16, 2021
    Assignee: VISTERRA, INC.
    Inventors: James R. Myette, Zachary Holmes Shriver, Karthik Viswanathan, Andrew M. Wollacott, Hedy Adari-Hall, Boopathy Ramakrishnan, Gregory Babcock
  • ANTIBODY MOLECULES TO A PROLIFERATION-INDUCING LIGAND (APRIL)
    Publication number: 20210032324
    Abstract: Antibody molecules that specifically bind to APRIL are disclosed. The antibody molecules can be used to treat, prevent, and/or diagnose disorders, such as IgA nephropathy.
    Type: Application
    Filed: October 20, 2020
    Publication date: February 4, 2021
    Inventors: James R. Myette, Zachary Holmes Shriver, Karthik Viswanathan, Andrew M. Wollacott, Hedy Adari-Hall, Boopathy Ramakrishnan, Gregory Babcock
  • INTERLEUKIN-2 AGENTS AND USES THEREOF
    Publication number: 20210024601
    Abstract: IL-2 agents that comprise IL-2 variants are disclosed as well as methods, compositions, and uses thereof. The IL-2 agents described herein can be used to treat and/or prevent various disorders and conditions.
    Type: Application
    Filed: July 24, 2020
    Publication date: January 28, 2021
    Inventors: Scott Moore Carlson, Gregory Babcock, Zachary Shriver, Boopathy Ramakrishnan
  • ANTIBODY MOLECULES TO A PROLIFERATION-INDUCING LIGAND (APRIL)
    Publication number: 20200331995
    Abstract: Antibody molecules that specifically bind to APRIL are disclosed. The antibody molecules can be used to treat, prevent, and/or diagnose disorders, such as IgA nephropathy.
    Type: Application
    Filed: June 25, 2020
    Publication date: October 22, 2020
    Inventors: James R. Myette, Zachary Holmes Shriver, Karthik Viswanathan, Andrew M. Wollacott, Hedy Adari-Hall, Boopathy Ramakrishnan, Gregory Babcock
  • ANTIBODY MOLECULES TO A PROLIFERATION-INDUCING LIGAND (APRIL)
    Publication number: 20200317770
    Abstract: Antibody molecules that specifically bind to APRIL are disclosed. The antibody molecules can be used to treat, prevent, and/or diagnose disorders, such as IgA nephropathy.
    Type: Application
    Filed: June 25, 2020
    Publication date: October 8, 2020
    Inventors: James R. Myette, Zachary Holmes Shriver, Karthik Viswanathan, Andrew M. Wollacott, Hedy Adari-Hall, Boopathy Ramakrishnan, Gregory Babcock
  • ANTIBODY MOLECULES TO A PROLIFERATION-INDUCING LIGAND (APRIL)
    Publication number: 20200299376
    Abstract: Antibody molecules that specifically bind to APRIL are disclosed. The antibody molecules can be used to treat, prevent, and/or diagnose disorders, such as IgA nephropathy.
    Type: Application
    Filed: June 10, 2020
    Publication date: September 24, 2020
    Inventors: James R. Myette, Zachary Holmes Shriver, Karthik Viswanathan, Andrew M. Wollacott, Hedy Adari-Hall, Boopathy Ramakrishnan, Gregory Babcock
  • ANTIBODY MOLECULES TO A PROLIFERATION-INDUCING LIGAND (APRIL)
    Publication number: 20190330326
    Abstract: Antibody molecules that specifically bind to APRIL are disclosed. The antibody molecules can be used to treat, prevent, and/or diagnose disorders, such as IgA nephropathy.
    Type: Application
    Filed: June 28, 2019
    Publication date: October 31, 2019
    Inventors: James R. Myette, Zachary Holmes Shriver, Karthik Viswanathan, Andrew M. Wollacott, Hedy Adari-Hall, Boopathy Ramakrishnan, Gregory Babcock
  • Isoform specific soluble FMS-like tyrosine kinase (sFlt) binding agents and uses thereof
    Patent number: 10421812
    Abstract: Aspects of the present disclosure relate to binding agents (e.g., antibodies and antigen binding fragments) that bind soluble fms-like tyrosine kinase 1 (sFlt1) in an isoform specific manner. In some embodiments, immunological assay methods utilizing isoform-specific antibodies or antigen binding fragments that bind sFlt1 isoforms are provided for assessing biological samples obtained from pregnant subjects, e.g., for purposes of evaluating preeclampsia status in the subject.
    Type: Grant
    Filed: March 31, 2016
    Date of Patent: September 24, 2019
    Assignee: University of Massachusetts
    Inventors: Teresa Broering, Colby Souders, Gregory Babcock, Naomi Boatright
  • Antibody molecules to a proliferation-inducing ligand (APRIL)
    Patent number: 10385123
    Abstract: Antibody molecules that specifically bind to APRIL are disclosed. The antibody molecules can be used to treat, prevent, and/or diagnose disorders, such as IgA nephropathy.
    Type: Grant
    Filed: December 7, 2018
    Date of Patent: August 20, 2019
    Assignee: VISTERRA, INC.
    Inventors: James R. Myette, Zachary Holmes Shriver, Karthik Viswanathan, Andrew M. Wollacott, Hedy Adari-Hall, Boopathy Ramakrishnan, Gregory Babcock
  • ANTIBODY MOLECULES TO DENGUE VIRUS AND USES THEREOF
    Publication number: 20190153074
    Abstract: Antibody molecules that specifically bind to dengue virus are disclosed. In certain embodiments, the antibody molecule bind to dengue virus serotypes DV-1, DV-2, DV-3, and DV-4. The antibody molecules can be used to treat, prevent, and/or diagnose dengue virus.
    Type: Application
    Filed: October 29, 2018
    Publication date: May 23, 2019
    Inventors: Luke Robinson, Zachary Shriver, James R. Myette, Gregory Babcock, Karthik Viswanathan
  • ANTIBODY MOLECULES TO APRIL AND USES THEREOF
    Publication number: 20190092851
    Abstract: Antibody molecules that specifically bind to APRIL are disclosed. The antibody molecules can be used to treat, prevent, and/or diagnose disorders, such as IgA nephropathy.
    Type: Application
    Filed: December 7, 2018
    Publication date: March 28, 2019
    Inventors: James R. Myette, Zachary Holmes Shriver, Karthik Viswanathan, Andrew M. Wollacott, Hedy Adari-Hall, Boopathy Ramakrishnan, Gregory Babcock
  • Antibody molecules to dengue virus and uses thereof
    Patent number: 10155806
    Abstract: Antibody molecules that specifically bind to dengue virus are disclosed. In certain embodiments, the antibody molecule bind to dengue virus serotypes DV-1, DV-2, DV-3, and DV-4. The antibody molecules can be used to treat, prevent, and/or diagnose dengue virus.
    Type: Grant
    Filed: May 16, 2016
    Date of Patent: December 18, 2018
    Assignee: VISTERRA, INC.
    Inventors: Luke Robinson, Zachary Shriver, James R. Myette, Gregory Babcock, Karthik Viswanathan
  • BINDING POLYPEPTIDES AND METHODS OF MAKING THE SAME
    Publication number: 20180201926
    Abstract: Polypeptides, such as antibody molecules and TCR molecules, and methods of making the same, are disclosed. The polypeptides can be used to treat, prevent, and/or diagnose disorders.
    Type: Application
    Filed: December 22, 2017
    Publication date: July 19, 2018
    Inventors: Zachary Shriver, Gregory Babcock, Luke Robinson
  • ANTIBODY MOLECULES TO ZIKA VIRUS AND USES THEREOF
    Publication number: 20170298119
    Abstract: Antibody molecules that specifically bind to Zika virus are disclosed. The antibody molecules can be used to treat, prevent, and/or diagnose Zika virus infection and disorders associated with Zika virus infection.
    Type: Application
    Filed: April 14, 2017
    Publication date: October 19, 2017
    Inventors: Andrew M. Wollacott, Luke Robinson, Gregory Babcock, Zachary Holmes Shriver
  • Anti-SOD1 antibodies and uses thereof
    Patent number: 9663586
    Abstract: The present invention features anti-SOD1 antibodies and methods of using the antibodies for the treatment of amyotrophic lateral sclerosis (ALS) or the amelioration of symptoms associated with ALS.
    Type: Grant
    Filed: July 28, 2015
    Date of Patent: May 30, 2017
    Assignee: University of Massachusetts
    Inventors: Donna Ambrosino, Gregory Babcock, Teresa Broering, Zuoshang Xu
  • ANTIBODY MOLECULES TO APRIL AND USES THEREOF
    Publication number: 20170145086
    Abstract: Antibody molecules that specifically bind to APRIL are disclosed. The antibody molecules can be used to treat, prevent, and/or diagnose disorders, such as IgA nephropathy.
    Type: Application
    Filed: November 23, 2016
    Publication date: May 25, 2017
    Inventors: James R. Myette, Zachary Holmes Shriver, Karthik Viswanathan, Andrew M. Wollacott, Hedy Adari-Hall, Boopathy Ramakrishnan, Gregory Babcock
  • ISOFORM SPECIFIC SOLUBLE FMS-LIKE TYROSINE KINASE (SFLT) BINDING AGENTS AND USES THEREOF
    Publication number: 20160347843
    Abstract: Aspects of the present disclosure relate to binding agents (e.g., antibodies and antigen binding fragments) that bind soluble fms-like tyrosine kinase 1 (sFlt1) in an isoform specific manner. In some embodiments, immunological assay methods utilizing isoform-specific antibodies or antigen binding fragments that bind sFlt1 isoforms are provided for assessing biological samples obtained from pregnant subjects, e.g., for purposes of evaluating preeclampsia status in the subject.
    Type: Application
    Filed: March 31, 2016
    Publication date: December 1, 2016
    Applicant: University of Massachusetts
    Inventors: Teresa Broering, Colby Souders, Gregory Babcock, Naomi Boatright